AudioCure Pharma Advances Trial Testing of AC102 for Sudden Hearing Loss Treatment
AudioCure Pharma has surpassed 50% patient enrollment in its Phase 2 trial testing AC102, a novel therapy to treat sudden hearing loss.
Tag: sudden hearing loss
All
Latest
All
Latest
‘BMJ’ Publishes ‘First Reported UK Case’ of Sudden Hearing Loss Linked to COVID-19
The doctors describe a case of a 45-year-old man with asthma who was referred to the ear, nose, and throat department at their hospital after suddenly experiencing hearing loss in one ear while being treated for COVID-19 infection as an inpatient.
All
Latest
Sensorion Receives European Medicines Agency Approval for PIP on Hearing Loss Treatment
SENS-401 is under development in the treatment of Sudden Sensorineural Hearing Loss (or SSNHL).
Sensorion Presents SENS-401 Data at Ci2018 Conference
Data from the presented studies showed that SENS-401 protected inner ear function and enhanced sensory hair cell survival in preclinical models of acoustic trauma and, separately, cisplatin infusion.
Read More
Auris Medical Holding AG Completes Patient Enrollment in Phase 3 Clinical Trial of Hearing Loss Drug
The HEALOS trial is a randomized, double-blind, placebo-controlled study evaluating the efficacy, safety, and tolerability of single-dose intratympanic administration of AM-111.
Read More
Drug to Treat Sudden Deafness Granted Orphan Drug Status by EMA
Strekin AG, Basal, Switzerland, announced that the European Medicines Agency (EMA) has granted orphan drug designation for the use of STR001 in the treatment of sudden sensorineural hearing loss, or sudden deafness.
Read More
Auris Medical Begins Phase 3 Trial for Sudden Deafness Drug
Auris Medical announced it has initiated patient enrollment in the ASSENT Phase 3 clinical trial of AM-111, a drug for treating idiopathic sudden sensorineural hearing loss, or sudden deafness. The drug must be administered within 72 hours after onset of hearing loss.
Read More
Auris Medical Enrolls First Patient in HEALOS Trial of Hearing Loss Drug
Auris Medical Holding AG, a Swiss biopharmaceutical company, announced enrollment of the first patient into the HEALOS clinical trial to test the drug, AM-111, as a therapy for sudden hearing loss. The trial involves 255 patients suffering from acute severe to profound hearing loss within 72 hours from onset.
Read More
People with Osteoporosis at Higher Risk for Sudden Deafness
According to a retrospective cohort study carried out in Taiwan, people with osteoporosis are at higher risk for sudden deafness.
Read MoreRehabilitative Aspects of ISSNHL
Amplification and bone conduction options for those with idiopathic sudden sensorineural hearing loss (ISSNHL), and why counseling is the key to success.
Read More
The Diagnostic and Treatment Dilemma of Sudden Sensorineural Hearing Loss
One of the keys to assisting the SSNHL patient is to understand the diagnostic and treatment pathways for the patient. This article looks at the evaluation, management, natural history, and rehabilitation of the SSNHL patient.
Read More
Steroid Therapy for Sudden Sensorineural Hearing Loss
Recent research at the Massachusetts Eye and Ear Infirmary and Harvard Medical School has significant implications for the use of steroid therapy with SSNHL patients.
Read More
Sudden Hearing Loss: A Team Approach to Assessment, Treatment, and Rehabilitation
Sudden hearing loss is a complex disorder with significant uncertainties and highly variable outcomes. A team approach is vital in efforts to achieve optimal outcomes.
Read MoreSudden Hearing Loss: Unique Challenges and Opportunities
An introduction to the topic of sudden sensorineural hearing loss (SSNHL), and a look at the issues and articles discussed in this special edition of The Hearing Review.
Read More